Colchicine and plaque: A focus on atherosclerosis imaging

Area of Science:

• Cardiology
• Pharmacology
• Immunology

Background:

• Colchicine is an established anti-inflammatory medication for autoimmune diseases.
• Emerging evidence highlights colchicine's efficacy in cardiovascular disease (CVD) management, including atherosclerotic plaque modification and coronary artery disease (CAD) treatment.
• The FDA's 2023 approval signifies a new era for colchicine in cardiovascular event reduction.

Purpose of the Study:

• To provide a comprehensive review of colchicine's emerging role in modifying atherosclerotic plaques.
• To offer a framework for physicians integrating colchicine into clinical practice for CVD management.
• To enhance understanding and application of colchicine in conjunction with existing CVD therapies.

Main Methods:

• Review of colchicine's anti-inflammatory mechanisms relevant to cardiovascular health.
• Analysis of large cohort studies demonstrating colchicine's impact on CAD.
• Synthesis of clinical trials assessing colchicine's effects on atherosclerotic plaque transformation.

Main Results:

• Colchicine demonstrates significant cardiovascular event reduction through its anti-inflammatory pathways.
• The medication influences atherosclerotic plaque transformation and reduction.
• Imaging modalities for atherosclerotic analysis are discussed in relation to colchicine's effects.

Conclusions:

• Colchicine represents a novel therapeutic option for CVD management, synergizing inflammation inhibition with lipid-lowering strategies.
• Physicians can leverage this review to effectively incorporate colchicine into patient care for CAD.
• Further understanding of colchicine's mechanistic effects on atherosclerosis will optimize its clinical application.